Federal Project Grant Award Summary

Medosome Biotec LLC received a $356,251 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) on July 15, 2026, with completion targeted for July 14, 2027. The company is developing genetically engineered probiotic organisms capable of producing and delivering glucagon-like peptide-1 (GLP-1) to address limitations associated with synthetic GLP-1 receptor agonists currently used to treat type 2 diabetes mellitus and obesity. The engineered probiotics will deliver GLP-1 both locally within the gastrointestinal tract and systemically through an oral delivery platform, potentially reducing the need for frequent injections while improving patient compliance and accessibility.

Beyond therapeutic peptide delivery, the project leverages the beneficial properties of probiotics to modulate gut microbiota, enhance intestinal health, and support immune function. This approach addresses significant clinical challenges including poor patient compliance, high discontinuation rates, global supply shortages, and cost barriers associated with conventional GLP-1-based therapies. Medosome Biotec's innovative probiotics platform has demonstrated proof-of-concept using Lactobacillus organisms and represents a next-generation therapeutic delivery system targeting multiple chronic metabolic diseases with potential for broader application across cardiovascular and immune disorders.